tiprankstipranks
Trending News
More News >

Robert Nelsen Insider Profile

32 Followers
Robert Nelsen, Director at Juno Therapeutics, holds 0.00 shares in Juno Therapeutics (Ticker: JUNO), holds ― shares in Sienna Biopharmaceuticals (Ticker: SNNAQ), holds 18.50M shares in Prime Medicine, Inc. (Ticker: PRME).
tipranks
Robert Nelsen

Robert Nelsen
Juno Therapeutics (JUNO)
Director

Ranked #15,180 out of 102,971 Corporate Insiders

Profitable Transactions

25%
3 out of 12 Profitable Transactions

Average Return

+11.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$959M
40.16%
14.84%
10.41%
7.90%
26.68% Others
A breakdown of Robert Nelsen's holdings

Insider Roles

Lyell Immunopharma
(LYEL)
Director, Ten Percent Owner
Denali Therapeutics
(DNLI)
Director
Alnylam Pharma
(ALNY)
Ten Percent Owner
Sana Biotechnology
(SANA)
Director, Ten Percent Owner
+8 other positions
Roles that Robert Nelsen holds in companies

Most Profitable Insider Trade

Stock:
Karuna Therapeutics
(KRTX)
Rating:Informative Buy
Date:Jul 02, 2019 - Jul 02, 2020
Return:+405.70%
The most profitable trade made by Robert Nelsen

Robert Nelsen's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
JUNO
Juno Therapeutics
Mar 07, 2018
Uninformative Sell
922.76M
$0.00
Sienna Biopharmaceuticals
Director, Ten Percent Owner
Denali Therapeutics
Jun 04, 2021
Director
Uninformative Buy
$142.31M
Unity Biotechnology
May 07, 2018
Director
Uninformative Buy
$904.34K
KRTX
Karuna Therapeutics
Apr 15, 2021
Uninformative Buy
$482.11M
Vir Biotechnology
Jun 03, 2024
Director
Uninformative Buy
$61.18M
Beam Therapeutics
Apr 02, 2021
Director, Ten Percent Owner
Uninformative Buy
$63.00M
Sana Biotechnology
Feb 12, 2024
Director, Ten Percent Owner
Informative Buy
10.00M
$75.79M
Lyell Immunopharma
Jun 23, 2021
Director, Ten Percent Owner
Uninformative Buy
$385.25M
Prime Medicine, Inc.
Aug 01, 2025
Director, Ten Percent Owner
Informative Buy
10.00M
$66.06M
Agios Pharma
Mar 07, 2017
Director
Informative Sell
2.06M
$62.10M
SAGE
SAGE Therapeutics
Nov 12, 2015
Uninformative Buy
$10.70M
BLPH
Bellerophon
Feb 23, 2015
Uninformative Buy
$11.59K
KYTH
Kythera
Mar 26, 2015
Informative Buy
108.26K
$771.92K
Alnylam Pharma
Ten Percent Owner
$99.88M
Fate Therapeutics
Oct 04, 2013
Director, Ten Percent Owner
Uninformative Buy
770.68K
$2.70M
NGSX
Neurogesx
Jul 26, 2011
Informative Buy
2.88M
$20.94K
Cyclacel Pharmaceuticals
Director, Ten Percent Owner
$0.00
List of latest transactions for each holding click on a transaction to see Robert Nelsen's performance on stock

Robert Nelsen insider profile FAQ

What is the percentage of profitable transactions made by Robert Nelsen?
The percentage of profitable transactions made by Robert Nelsen is 25%.
    What is the average return per transaction made by Robert Nelsen?
    The average return per transaction made by Robert Nelsen is 11.40%.
      What stocks does Robert Nelsen hold?
      Robert Nelsen holds: JUNO, SNNAQ, DNLI, UNBX, KRTX, VIR, BEAM, SANA, LYEL, PRME, AGIO, SAGE, BLPH, KYTH, ALNY, FATE, NGSX, CYCC stocks.
        What was Robert Nelsen’s latest transaction?
        Robert Nelsen latest transaction was an Uninformative Sell of $922.76M.
          What was Robert Nelsen's most profitable transaction?
          Robert Nelsen’s most profitable transaction was an Informative Buy of KRTX stock on July 2, 2019. The return on the trade was 405.70%.
            What is Robert Nelsen's role in Juno Therapeutics?
            Robert Nelsen's role in Juno Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.